Received Feb 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | — |
Medical assistant calling on behalf of nurse practitioner. She states they had a patient in the office yesterday who had received their first dose of MMRII in 2023 and experienced "red bumps, generalized rash and a fever of 105 F" 4 days after admini; red bumps, generalized rash and a fever of 105 F"; red bumps, generalized rash and a fever of 105 F"; This spontaneous report was received from a nurse practitioner via another health professional and refers to a 2-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), dose number 1, (administration route, anatomical location, lot # and expiration date were not reported) diluted with a sterile diluent (Hollister-Stier STERILE DILUENT) (administration route, anatomical location, lot # and expiration date were not reported) as prophylaxis. On an unspecified date in 2023, the patient experienced "red bumps, generalized rash and a fever of 105 F" 4 days after the vaccine administration. This vaccine was given at another clinic so many details were unknown. The nurse practitioner was questioning if the next dose was recommended after the patient experienced such a "severe" reaction the first time. At the reporting time, the patient recovered from the events of red bumps, generalized rash and a fever of 105 F on an unspecified date. The causal relationship between the events of red bumps, generalized rash and a fever of 105 F and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) were not reported. Lot # is being requested and will be submitted if received.
Sterile diluent
Test Date: 2023; Test Name: Body temperature; Result Unstructured Data: 105 [degF]